Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 142,886 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 142,886 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98. Following the completion of the transaction, the chief financial officer now directly owns 112,186 shares of the company’s stock, valued at $3,357,726.98. This represents a 56.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.96, for a total value of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.79, for a total value of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total value of $169,491.40.

Hims & Hers Health Stock Down 2.9 %

NYSE HIMS traded down $0.60 on Friday, reaching $20.25. The company had a trading volume of 6,051,112 shares, compared to its average volume of 9,139,706. The stock has a market capitalization of $4.35 billion, a P/E ratio of 47.38 and a beta of 1.06. The company’s fifty day moving average is $19.64 and its 200 day moving average is $18.78. Hims & Hers Health, Inc. has a 52-week low of $7.40 and a 52-week high of $30.44.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the prior year, the firm posted ($0.04) EPS. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC increased its position in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC increased its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $111,000. Finally, Amalgamated Bank increased its position in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on HIMS. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating in a report on Thursday. Piper Sandler restated a “neutral” rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, TD Cowen increased their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $21.21.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.